Pharmacokinetic evaluation of fosaprepitant dimeglumine
Authors:
- 26 August 2010
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 6 (10) , 1277-1286
Abstract
Importance of the field: Chemotherapy induced nausea and vomiting (CINV) is a common complication in the treatment of patients with cancer. The introduction of the first in class neurokinin-1 recep...Keywords
This publication has 28 references indexed in Scilit:
- AprepitantDrugs, 2009
- Lack of Effect of Aprepitant or Its Prodrug Fosaprepitant on QTc Intervals in Healthy SubjectsAnesthesia & Analgesia, 2009
- Chemotherapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxisAnnals of Oncology, 2009
- The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drugInvestigational New Drugs, 2009
- Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present, and Future RecommendationsThe Oncologist, 2007
- Cost-Effectiveness of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic ChemotherapyValue in Health, 2007
- Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatmentAnnals of Oncology, 2006
- Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment responseSupportive Care in Cancer, 2006
- Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus ConferenceAnnals of Oncology, 2005
- Prevention of cisplatin‐induced acute and delayed emesis by the selective neurokinin‐1 antagonists, L‐758,298 and MK‐869Cancer, 2002